argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
argenx (Euronext & Nasdaq: ARGX) will hold an Extraordinary General Meeting of Shareholders at 15:00 CEST on September 17, 2026 at Freshfields LLP, Strawinskylaan 10, Amsterdam.
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) will hold an Extraordinary General Meeting of Shareholders at 15:00 CEST on September 17, 2026 at Freshfields LLP, Strawinskylaan 10, Amsterdam. Shareholders may attend in person or by proxy, with e-voting and meeting documentation available via the argenx and ABN AMRO websites.
Details
News Market Reaction – ARGX
On Aug 4, the first trading day after this news, ARGX closed 1.65% above the previous close.
Data tracked by StockTitan Argus for the Aug 4 session.
Key Figures
- Meeting date
- September 17, 2026
- Extraordinary General Meeting
- Meeting time
- 15:00 CEST
- Extraordinary General Meeting
- Voting items
- 2
- Proposed non-executive director appointments
- Announcement date
- August 3, 2026
- Article dateline
Historical Context
-
Cash acquisition of Forte Biosciences for $77 per share and approximately $2.2 billion equity value
-
Second-quarter product sales reached $1.5 billion, with operating profit of $494 million
-
Company scheduled its half-year results and second-quarter update for July 23
-
Company announced an autoimmune myositis research and development webinar
-
EULAR presentation highlighted sustained benefit and safety across 834 patients
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non- executive directors regulatory
e-voting system technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
August 3, 2026 – 22:01 PM CEST
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of Shareholders will be held at 15:00 CEST on Thursday, September 17, 2026 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.
The shareholders and all other persons entitled to attend the Extraordinary General Meeting are invited to attend. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.
Agenda
The two voting items on the agenda will be the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non- executive directors of the Company’s Board of Directors.
The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
About argenx
argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.